RJA
SCPH

Raymond James & Associates’s scPharmaceuticals SCPH Stock Holding History

Raymond James & Associates’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$368K Sell
80,706
-5,353
-6% -$25.9K ﹤0.01% 3286
2024
Q2 		$374K Buy
86,059
+1,010
+1% +$4.44K ﹤0.01% 3245
2024
Q1 		$427K Sell
85,049
-2,000
-2% -$11.2K ﹤0.01% 3155
2023
Q4 		$546K Buy
87,049
+5,377
+7% +$30.8K ﹤0.01% 2909
2023
Q3 		$582K Buy
81,672
+4,420
+6% +$34.8K ﹤0.01% 2800
2023
Q2 		$787K Buy
77,252
+7,401
+11% +$77.2K ﹤0.01% 2631
2023
Q1 		$634K Buy
69,851
+18,093
+35% +$133K ﹤0.01% 2773
2022
Q4 		$371K Buy
+51,758
New +$316K ﹤0.01% 3085

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Raymond James & Associates's SCPH Position: Q3 2024 in Review

Raymond James & Associates reduced its scPharmaceuticals (SCPH) stake by 6.2% in Q3 2024, selling an estimated $25.9K and leaving 80,706 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #3286.

Raymond James & Associates first reported a position in SCPH in Q4 2022 and has held it in 8 quarters since. The position peaked at $787K in Q2 2023. 95 funds tracked by Wall St. Rank hold SCPH as of Q3 2024.

  • Raymond James & Associates held 80,706 shares of scPharmaceuticals worth $368K as of Q3 2024.
  • Raymond James & Associates sold 5,353 scPharmaceuticals shares in Q3 2024, an estimated $25.9K.
  • scPharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3286 holding.
  • Raymond James & Associates first reported a position in scPharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • Raymond James & Associates's scPharmaceuticals position peaked at $787K in Q2 2023.
  • 95 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.